Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) traded down 2.5% on Wednesday. The stock traded as low as C$0.38 and last traded at C$0.39. Approximately 82,525 shares changed hands during trading, a decline of 5% from the average session volume of 87,218 shares. The stock had previously closed at C$0.40.
Medicenna Therapeutics Stock Performance
The company has a debt-to-equity ratio of 6.22, a current ratio of 1.25 and a quick ratio of 4.65. The company has a market capitalization of C$36.00 million, a PE ratio of -1.77 and a beta of 3.00. The company has a 50 day moving average of C$0.41 and a two-hundred day moving average of C$0.48.
Medicenna Therapeutics Company Profile
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
Further Reading
- Five stocks we like better than Medicenna Therapeutics
- Saddle Up: Texas Stock Exchange Ropes In $80 Billion in Listings
- Why Concentra’s Quiet Healthcare Business Keeps Winning
- Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
- Alamos Gold’s 1 Million-Ounce Growth Story Is Hiding in Plain Sight
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
